ATM and breast cancer: More specifically, ATM knockdown via siRNA oligos in breast cancer SK-BR3 and MDA-MB231 cells (Fig. 4c) or ATM knockout in mouse embryonic fibroblasts (MEFs) (Fig. 4d) extended TOP2β protein half-life upon VM-26 treatment (Fig. 4c, d).